Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIE-ADC
- Development stage
- Preclinical
- Lead developer
- TRIO Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TIE-ADC (Tumor Immunity Enhancing Antibody-Drug Conjugate) is a preclinical dual-targeting antibody-drug conjugate being developed by Trio Pharmaceuticals (also known as Trio Biotech). It represents a novel therapeutic approach designed to simultaneously address two tumor-promoting mechanisms within a single molecule. The platform utilizes a dual-targeting strategy intended to kill both cancer cells and immunosuppressive cells in the tumor microenvironment, thereby removing tumor-mediated immunosuppression and enhancing the anti-tumor immune response. While the specific molecular targets for the cancer cells and immunosuppressor cells have not been publicly disclosed, the drug is currently in preclinical development for the treatment of Triple Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC).
- Brand names
- Tumor Immunity Enhancing Antibody-Drug Conjugate
- Other names
- TIE-ADC (TNBC/NSCLC)
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on TIE-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIE-ADC.